Editorial
SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract with an annual incidence rate of 7 to 10 per one million people (1,2).
